Thiazole based heterocycle as promising multi target antimicrobial agent
No Thumbnail Available
Date
2026-06
Journal Title
Journal ISSN
Volume Title
Publisher
AIKTC
Abstract
Development of antimicrobial resistance (AMR) is currently one of the most concerning global health issues, which requires new scaffolds with unique mechanisms of action and superior safety profiles. Thiazoles are privileged chemotypes having been proved their antibacterial and antifungal effects towards multidrug-resistant bacteria such as Escherichia coli, Staphylococcus aureus as well as opportunistic fungi. In the current research, two novel thiazoles (TH01 and TH02) have been synthesized through the Hantzsch-type cyclization reaction using thiosemicarbazides as the starting point; structure elucidation was achieved using FTIR and LC-MS techniques. Mapping the scientific publications (2023-2026) showed an explosive increase in the number of papers discussing the application of thiazoles as antimicrobials. Network pharmacological approach to the new compound TH02 in combination with data from GeneCards, STRING, GO, and KEGG enrichment analysis suggested the following hub-targets as main targets (EGFR, SRC, MAPK14, PTGS1, FYN, LCK); moreover, many host-related signaling pathways involved in immunity, inflammation, and infection processes can be considered targets for TH02 during E. coli and S. aureus infections. Molecular docking with several protein structures (5EQG, 1YOL, 3LCK, 2A4Z) revealed that TH02 had much better binding energy compared to the reference drug fluconazole, which indicates its multimodal nature.